The George Institute for Global Health, The University of Sydney, Sydney, Australia; Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia.
Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia; Australian and New Zealand Dialysis and Transplant Registry (ANZDATA), Adelaide, Australia; Sydney Medical School, University of Sydney, Sydney, Australia.
Am J Kidney Dis. 2014 Sep;64(3):359-66. doi: 10.1053/j.ajkd.2014.02.023. Epub 2014 Apr 29.
Late referral for renal replacement therapy (RRT) leads to worse outcomes. In 2005, estimated glomerular filtration rate (eGFR) reporting began in Australasia, with an aim of substantially increasing earlier disease detection.
Observational cohort study using the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) data.
SETTING & PARTICIPANTS: All patients commencing RRT in Australasia between January 1, 1999, and December 31, 2010. We excluded the period between December 31, 2004, and January 1, 2007, to allow for practice change.
Introduction of eGFR reporting.
Primary outcome was late referral defined as commencing RRT within 3 months of nephrology referral. Secondary outcomes included initial RRT modality and prepared access at hemodialysis therapy initiation.
Late referral rates per era were determined and multilevel logistic regression was used to identify late referral predictors.
We included 25,009 patients. Overall, 3,433 (25.3%) patients were referred late in the pre-eGFR era compared with 2,464 (21.6%) in the post-eGFR era, for an absolute reduction of 3.7% (95% CI, 2.7%-4.8%; P<0.001). After adjustments for age, body mass index, race, comorbid conditions, and primary kidney disease, adjusted late referral rates were 25.8% (95% CI, 23.3%-28.3%) and 21.8% (95% CI, 19.2%-24.4%) in the pre- and post-eGFR eras, respectively, for a difference of 4.0% (95% CI, 1.2%-6.8%; P=0.005). Late referral risk was attenuated significantly post-eGFR reporting (OR, 1.30; 95% CI, 1.12-1.51) compared to pre-eGFR reporting (OR, 2.15; 95% CI, 1.88-2.46) for indigenous patients. Late referral rates decreased for older patients but increased slightly for younger patients (P=0.001 for interaction between age and era). There was no impact on initial RRT modality or prepared access rates at hemodialysis therapy initiation between eras.
Residual confounding could not be excluded.
eGFR reporting was associated with small reductions in late referral, but more than 1 in 5 patients are still referred late. Other initiatives to increase timely referral warrant investigation.
肾脏替代治疗(RRT)的延迟转介会导致更差的结果。2005 年,澳大利亚和新西兰开始报告估算肾小球滤过率(eGFR),旨在大幅提高早期疾病检测率。
利用澳大利亚和新西兰透析和移植登记处(ANZDATA)的数据进行观察性队列研究。
1999 年 1 月 1 日至 2010 年 12 月 31 日期间在澳大利亚开始接受 RRT 的所有患者。我们排除了 2004 年 12 月 31 日至 2007 年 1 月 1 日期间,以允许实践改变。
eGFR 报告的引入。
主要结果是定义为在肾脏病转介后 3 个月内开始 RRT 的晚期转介。次要结果包括初始 RRT 方式和开始血液透析治疗时准备好的通路。
确定每个时代的晚期转诊率,并使用多水平逻辑回归来确定晚期转诊的预测因素。
我们纳入了 25009 名患者。总体而言,在 eGFR 时代之前,有 3433 名(25.3%)患者被晚期转介,而在 eGFR 时代之后,有 2464 名(21.6%)患者被晚期转介,绝对减少了 3.7%(95%CI,2.7%-4.8%;P<0.001)。在调整年龄、体重指数、种族、合并症和主要肾脏疾病后,在 eGFR 时代之前和之后,调整后的晚期转诊率分别为 25.8%(95%CI,23.3%-28.3%)和 21.8%(95%CI,19.2%-24.4%),差异为 4.0%(95%CI,1.2%-6.8%;P=0.005)。与 eGFR 报告前相比(OR,1.30;95%CI,1.12-1.51),eGFR 报告后晚期转诊的风险显著降低(OR,2.15;95%CI,1.88-2.46)对于土著患者。老年患者的晚期转诊率下降,但年轻患者的晚期转诊率略有上升(年龄与时代之间的交互作用 P=0.001)。在两个时代之间,初始 RRT 方式或血液透析治疗开始时准备好的通路率没有影响。
无法排除残留混杂因素。
eGFR 报告与晚期转诊的少量减少相关,但仍有超过 1/5 的患者被晚期转介。需要调查其他提高及时转诊的措施。